AMDL's Jade Pharmaceutical Subsidiary Announces Completion of a New, Accelerated Product R&D Process
July 18 2007 - 8:30AM
PR Newswire (US)
TUSTIN, Calif., July 18 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), headquartered in Tustin, California, with operations in
Shenzhen, Jiangxi and Jilin China, through its wholly owned
subsidiary Jade Pharmaceutical Inc. (JPI), is an international
biopharma company that engages in the development, manufacture and
marketing of proprietary pharmaceutical and diagnostic products.
AMDL announced today that JPI has completed an accelerated, new
Corporate Research and Development Process. Mr. Frank Zheng,
Managing Director of JPI, stated that, "JPI's R&D process
focuses on four different strategies that include: in-house product
development; licensing global patents from international
universities and research centers; licensing China based patents
from international research companies; and the collaboration with
global drug development companies." Mr. Gary Dreher, CEO of AMDL
stated, "These efforts will strengthen our pipeline for JPI's
growing family of products, which will ensure our future. JPI's
R&D collaborative process is a well organized asset, which
means that we can bring products to market and therefore realize
profits sooner. Jade has the potential to build 100 million in
annual sales within the next 4 to 5 years." The JPI Research and
Development Platform now includes a 30 person technical team, a 50
person support staff, which is coupled with 10 various consulting
relationships. These R&D consulting relationships are the
backbone of JPI's collaborative product development process. The
four key R&D Senior Consultants for JPI are: Prof. Zhao Guo
Qing, an expert on plant biology, who is a Professor of Shanghai
Second Military Medical University and a visiting professor of
Harvard Medical School; Prof. Chen Zhong, an expert on galenic
pharmacy, who is a senior consultant at Peking Union Medical
College Hospital and a Professor of Jiangxi Medical College; Prof.
Zhang Ming Li, President of Pharmacy Research Institute at China
Military Medical College; and Prof. Li Shu Zi, Vice President of Ji
Lin Traditional Chinese Medicine Research Institute and a Member of
Traditional Chinese Medicine Quality Assurance Committee. JPI's
R&D process takes place at seven locations in China. Two of
these are in-house R&D facilities that include the Research
Center of YYB, located in Jiangxi, and the Research Center at JJB,
located in Jilin. Additionally, five collaborative R&D
facilities include: Jilin Traditional Chinese Medicine Research
Institute; Baiqiuen Pharmaceutical Research Institute; Research
Center of Nanjing Pharmacy University; Jiangxi Bikang Technology
Development Co. Ltd.; and the Changsha Continental Pharmaceutical
Research Institute. About Jade: Jade has access to the fastest
growing pharmaceutical and consumer market in the world: China.
AMDL, through its subsidiary, Jade currently manufactures large
volume injection fluids, tablets and other related products,
holding licenses for 133 products. It also manufactures 107
generic, over the counter and supplemental pharmaceutical products
under certified Chinese Good Manufacturing Practice (CGMP)
standards. About AMDL: More information about AMDL and its products
can be obtained at http://www.amdl.com/. Forward-Looking
Statements: This news release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such statements are subject to certain risks and
uncertainties, and actual circumstances, events or results may
differ materially from those projected in such forward-looking
statements. The Company cautions readers not to place undue
reliance on any forward-looking statements. The Company does not
undertake, and specifically disclaims any obligation, to update or
revise such statements to reflect new circumstances or
unanticipated events as they occur. Contact: AMDL, Inc. Mr. Paul
Knopick AMDL Investor Relations Direct Line: 949.707.5365 Voice
Mail: 714.505.4460 DATASOURCE: AMDL, Inc. CONTACT: Paul Knopick,
+1-949-707-5365, +1-714-505-4460 voice mail, for AMDL Investor
Relations Web site: http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2023 to Jul 2024